Display options
Cite
Yen HL, Valkenburg S, Sia SF, et al. Cellular tropism of SARS-CoV-2 in the respiratory tract of Syrian hamsters and B6.Cg-Tg(K18-ACE2)2Prlmn/J transgenic mice. Vet Pathol. 2021;3009858211043084doi: 10.1177/03009858211043084.
Yen, H. L., Valkenburg, S., Sia, S. F., Choy, K. T., Peiris, J. S. M., Wong, K. H. M., Crossland, N., Douam, F., & Nicholls, J. M. (2021). Cellular tropism of SARS-CoV-2 in the respiratory tract of Syrian hamsters and B6.Cg-Tg(K18-ACE2)2Prlmn/J transgenic mice. Veterinary pathology, 3009858211043084. https://doi.org/10.1177/03009858211043084
Yen, Hui-Ling, et al. "Cellular tropism of SARS-CoV-2 in the respiratory tract of Syrian hamsters and B6.Cg-Tg(K18-ACE2)2Prlmn/J transgenic mice." Veterinary pathology vol. (2021): 3009858211043084. doi: https://doi.org/10.1177/03009858211043084
Yen HL, Valkenburg S, Sia SF, Choy KT, Peiris JSM, Wong KHM, Crossland N, Douam F, Nicholls JM. Cellular tropism of SARS-CoV-2 in the respiratory tract of Syrian hamsters and B6.Cg-Tg(K18-ACE2)2Prlmn/J transgenic mice. Vet Pathol. 2021 Sep 01;3009858211043084. doi: 10.1177/03009858211043084. Epub 2021 Sep 01. PMID: 34467820; PMCID: PMC8721337.
Copy Download .nbib Format: NLM
Share it on

Vet Pathol. 2021 Sep 01;3009858211043084. doi: 10.1177/03009858211043084. Epub 2021 Sep 01.

Cellular tropism of SARS-CoV-2 in the respiratory tract of Syrian hamsters and B6.Cg-Tg(K18-ACE2)2Prlmn/J transgenic mice.

Veterinary pathology

Hui-Ling Yen, Sophie Valkenburg, Sin Fun Sia, Ka Tim Choy, J S Malik Peiris, Karen H M Wong, Nicholas Crossland, Florian Douam, John M Nicholls

Affiliations

  1. The University of Hong Kong, Pok Fu Lam, Hong Kong.
  2. Boston University, Boston, MA, USA.

PMID: 34467820 PMCID: PMC8721337 DOI: 10.1177/03009858211043084

Abstract

Several animal models have been developed to study the pathophysiology of SARS-CoV-2 infection and to evaluate vaccines and therapeutic agents for this emerging disease. Similar to infection with SARS-CoV-1, infection of Syrian hamsters with SARS-CoV-2 results in moderate respiratory disease involving the airways and lung parenchyma but does not lead to increased mortality. Using a combination of immunohistochemistry and transmission electron microscopy, we showed that the epithelium of the conducting airways of hamsters was the primary target for viral infection within the first 5 days of infection, with little evidence of productive infection of pneumocytes. At 6 days postinfection, antigen was cleared but parenchymal damage persisted, and the major pathological changes resolved by day 14. These findings are similar to those previously reported for hamsters with SARS-CoV-1 infection. In contrast, infection of K18-hACE2 transgenic mice resulted in pneumocyte damage, with viral particles and replication complexes in both type I and type II pneumocytes together with the presence of convoluted or cubic membranes; however, there was no evidence of virus replication in the conducting airways. The Syrian hamster is a useful model for the study of SARS-CoV-2 transmission and vaccination strategies, whereas infection of the K18-hCE2 transgenic mouse results in lethal disease with fatal neuroinvasion but with sparing of conducting airways.

Keywords: COVID-19; SARS-CoV-2; coronavirus; immunohistochemistry; pathology; severe acute respiratory syndrome; ultrastructure

References

  1. Front Cell Dev Biol. 2021 Mar 12;9:630242 - PubMed
  2. Nat Microbiol. 2020 Nov;5(11):1439-1448 - PubMed
  3. J Virol. 2020 Sep 15;94(19): - PubMed
  4. Immunity. 2021 Mar 9;54(3):557-570.e5 - PubMed
  5. Emerg Microbes Infect. 2021 Dec;10(1):291-304 - PubMed
  6. Am J Respir Cell Mol Biol. 2020 Dec;63(6):856-859 - PubMed
  7. J Exp Med. 2021 Mar 1;218(3): - PubMed
  8. Stem Cell Reports. 2016 Nov 8;7(5):817-825 - PubMed
  9. Crit Care. 2020 Oct 6;24(1):594 - PubMed
  10. Sci Adv. 2021 May 26;7(22): - PubMed
  11. Lancet Respir Med. 2020 Jul;8(7):687-695 - PubMed
  12. Transbound Emerg Dis. 2021 Jul;68(4):1868-1885 - PubMed
  13. Respirology. 2021 Jul;26(7):652-665 - PubMed
  14. Proc Natl Acad Sci U S A. 2021 Mar 23;118(12): - PubMed
  15. PLoS Med. 2006 Feb;3(2):e27 - PubMed
  16. Virus Res. 2008 Apr;133(1):20-32 - PubMed
  17. Nature. 2021 Feb;590(7845):320-325 - PubMed
  18. Clin Infect Dis. 2021 Aug 2;73(3):e719-e734 - PubMed
  19. JCI Insight. 2021 Jan 11;6(1): - PubMed
  20. J Gen Virol. 2004 Jun;85(Pt 6):1655-1663 - PubMed
  21. Nature. 2020 Oct;586(7830):509-515 - PubMed
  22. Cell Stem Cell. 2020 Apr 2;26(4):482-502 - PubMed
  23. Front Immunol. 2020 Aug 28;11:2163 - PubMed
  24. Nature. 2020 Aug;584(7821):450-456 - PubMed
  25. Vet Res Commun. 2021 Feb;45(1):1-19 - PubMed
  26. J Natl Cancer Inst. 1978 Aug;61(2):551-61 - PubMed
  27. Viruses. 2021 Apr 08;13(4): - PubMed
  28. Viral Immunol. 2010 Oct;23(5):509-19 - PubMed
  29. Vaccines (Basel). 2020 Dec 17;8(4): - PubMed
  30. Virchows Arch. 2020 Sep;477(3):359-372 - PubMed
  31. Nature. 2020 Jul;583(7818):834-838 - PubMed
  32. Am J Pathol. 1989 Jan;134(1):79-87 - PubMed
  33. Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595 - PubMed
  34. J Virol. 2008 Oct;82(19):9465-76 - PubMed
  35. Biomed Pharmacother. 2021 Jun;138:111457 - PubMed
  36. J Virol. 2021 Feb 26;: - PubMed
  37. Viruses. 2021 Feb 27;13(3): - PubMed
  38. Br J Pharmacol. 2020 Dec;177(24):5679-5681 - PubMed
  39. JCI Insight. 2020 Dec 3;5(23): - PubMed
  40. Br J Pharmacol. 2020 Nov;177(21):4851-4865 - PubMed
  41. Am J Physiol Lung Cell Mol Physiol. 2020 Jul 1;319(1):L115-L120 - PubMed
  42. Rev Med Virol. 2021 Jul;31(4):e2196 - PubMed
  43. J Infect Dis. 1964 Jun;114:226-34 - PubMed
  44. J Virol. 2005 Jan;79(1):503-11 - PubMed
  45. Proc Natl Acad Sci U S A. 2020 Oct 27;117(43):26955-26965 - PubMed
  46. Mucosal Immunol. 2020 Nov;13(6):877-891 - PubMed
  47. Transbound Emerg Dis. 2021 Jul;68(4):1850-1867 - PubMed
  48. Life Sci Alliance. 2021 Feb 11;4(4): - PubMed
  49. Lancet. 2003 May 24;361(9371):1773-8 - PubMed
  50. PLoS Pathog. 2021 Mar 25;17(3):e1009383 - PubMed
  51. Viruses. 2020 Jul 20;12(7): - PubMed

Publication Types